復星醫藥(02196.HK):復星醫藥產業於中國大陸境內就FCN-159片用於I型神經纖維瘤的治療啟動II期臨牀研究
格隆匯11月26日丨復星醫藥(02196.HK)公佈,近日,公司控股子公司上海復星醫藥產業發展有限公司(以下簡稱"復星醫藥產業")於中國大陸境內就FCN-159片(以下簡稱"該新藥")用於I型神經纖維瘤的治療啟動II期臨牀研究。
該新藥為集團(即公司及控股子公司單位,下同)自主研發的創新型小分子化學藥物,為MEK1/2選擇性抑制劑,擬主要用於晚期實體瘤、I型神經纖維瘤的治療。截至公吿日,除本次用於I型神經纖維瘤治療於中國境內啟動II期臨牀研究外,該新藥用於具有NRAS突變的晚期黑色素瘤治療於中國境內處於I期臨牀試驗階段、用於治療成人和兒童I型神經纖維瘤(NF1)已於美國獲臨牀試驗批准。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.